Abstract
To figure out the pathway by which epigallocatechin gallate restrains angiogenesis and glycolysis in colorectal cancer through the circular ribonucleic acid (actin gamma 2)/microRNA-370-5p axis. Detection of circular actin gamma 2 and microRNA-370-5p in colorectal cancer patient tissues and cells and vascular endothelial growth factor A in colorectal cancer cells was conducted. Cell viability and proliferation, angiogenesis, glucose and lactate of colorectal cancer cells were examined. Circular actin gamma 2 and microRNA-370-5p's combination link was verified. Epigallocatechin gallate restrained cell viability, angiogenesis and glycolysis in colorectal cancer cells. In tissues and cells of colorectal cancer patients, circular actin gamma 2 was elevated but microRNA-370-5p was reduced. Elevation of circular actin gamma 2 or repression of microRNA-370-5p motivated vascular endothelial growth factor A, cell proliferation, angiogenesis and glycolysis in colorectal cancer cells. Meanwhile, it was demonstrated that circular actin gamma 2 competitively combined with microRNA-370-5p. MicroRNA-370-5p inhibitor turned around the repressive effect of epigallocatechin gallate and knockdown of circular actin gamma 2 on colorectal cancer progression. Circular actin gamma 2 competitively combines with microRNA-370-5p to control colorectal cancer progression and epigallocatechin gallate restrains colorectal cancer angiogenesis and glycolysis through the circular actin gamma 2/microRNA-370-5p pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
